Sutro Biopharma announces FDA clearance for IND application of STRO-004 and upcoming virtual R&D day

CAR-T Digest - August 2020

06 November 2025: Sutro Biopharma announces FDA clearance for IND application of STRO-004 and upcoming virtual R&D day

Sutro Biopharma received FDA IND clearance for STRO-004, a potential best-in-class Tissue Factor-targeting ADC, marking a key milestone toward clinical evaluation
The company plans to initiate patient dosing by the end of 2025, advancing its pipeline into the next stage of development
Preclinical data presented at major conferences demonstrated strong potential of STRO-004 and other dual-payload ADCs to address treatment resistance
Sutro will host a virtual R&D Day on November 12, 2025, to provide program and pipeline updates
With $167.6 million in cash reserves, the company maintains funding support into mid-2027 while progressing its most promising ADC assets